Serial Assessment of Depression and Anxiety by Patients and Providers in Women Receiving Chemotherapy for Early Breast Cancer.
Zev M NakamuraAllison M DealKirsten A NyropYi Tang ChenLaura J QuillenTucker BrenizerHyman B MussPublished in: The oncologist (2020)
In this sample of 256 patients with breast cancer, depression and anxiety, measured using single-item toxicity reports completed by patients and providers, were very common during adjuvant or neoadjuvant chemotherapy. Patient-reported depression and anxiety of at least moderate severity were associated with multiple objective indicators of psychiatric need. Unfortunately, providers underrecognized the severity of their patients' mental health symptoms. The use of patient-reported, single-item toxicity reports can be incorporated into routine oncology practice and provide clinically meaningful information regarding patients' psychological health.
Keyphrases
- patient reported
- end stage renal disease
- mental health
- newly diagnosed
- ejection fraction
- neoadjuvant chemotherapy
- chronic kidney disease
- prognostic factors
- healthcare
- early stage
- squamous cell carcinoma
- radiation therapy
- public health
- oxidative stress
- metabolic syndrome
- lymph node
- adipose tissue
- physical activity
- risk assessment
- locally advanced
- quality improvement
- sleep quality
- mental illness
- pregnancy outcomes